Nomura Asset Management’s AbCellera Biologics ABCL Stock Holding History

Nomura Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-86,624	Closed	-$392K	–	1505
2024 Q1	$392K	Hold	86,624	–	–	﹤0.01%	852
2023 Q4	$495K	Hold	86,624	–	–	﹤0.01%	849
2023 Q3	$398K	Hold	86,624	–	–	﹤0.01%	863
2023 Q2	$560K	Hold	86,624	–	–	﹤0.01%	851
2023 Q1	$653K	Hold	86,624	–	–	﹤0.01%	836
2022 Q4	$878K	Sell	86,624 -8,938	-9%	-$103K	0.01%	817
2022 Q3	$945K	Hold	95,562	–	–	0.01%	796
2022 Q2	$1.02M	Buy	95,562 +40,732	+74%	+$345K	0.01%	811
2022 Q1	$535K	Hold	54,830	–	–	﹤0.01%	887
2021 Q4	$784K	Buy	+54,830	New	+$832K	﹤0.01%	875

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Nomura Asset Management's ABCL Position: Q2 2024 in Review

Nomura Asset Management sold out of AbCellera Biologics (ABCL) in Q2 2024, closing a stake of 86,624 shares — an estimated $392K sold.

Nomura Asset Management first reported a position in ABCL in Q4 2021 and held it in 10 quarters. The position peaked at $1.02M in Q2 2022. 147 funds tracked by Wall St. Rank hold ABCL as of Q2 2024.

Nomura Asset Management reported no remaining AbCellera Biologics position as of Q2 2024 after selling out during the quarter.
Nomura Asset Management sold 86,624 AbCellera Biologics shares in Q2 2024, an estimated $392K.
Nomura Asset Management first reported a position in AbCellera Biologics in Q4 2021 and held it in 10 quarters.
Nomura Asset Management's AbCellera Biologics position peaked at $1.02M in Q2 2022.
147 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2024.

Based on Nomura Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.